Janney Capital Management LLC Lowers Stake in Johnson & Johnson (NYSE:JNJ)

Janney Capital Management LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,710 shares of the company’s stock after selling 410 shares during the quarter. Johnson & Johnson makes up approximately 1.0% of Janney Capital Management LLC’s portfolio, making the stock its 29th largest holding. Janney Capital Management LLC’s holdings in Johnson & Johnson were worth $15,511,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Private Wealth Partners LLC lifted its stake in Johnson & Johnson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 80,427 shares of the company’s stock valued at $13,034,000 after buying an additional 4,234 shares in the last quarter. Optas LLC lifted its stake in Johnson & Johnson by 11.4% in the 3rd quarter. Optas LLC now owns 5,779 shares of the company’s stock valued at $937,000 after buying an additional 592 shares in the last quarter. Clear Creek Financial Management LLC lifted its stake in Johnson & Johnson by 20.1% in the 3rd quarter. Clear Creek Financial Management LLC now owns 6,106 shares of the company’s stock valued at $990,000 after buying an additional 1,024 shares in the last quarter. Lmcg Investments LLC lifted its stake in Johnson & Johnson by 32.7% in the 3rd quarter. Lmcg Investments LLC now owns 87,162 shares of the company’s stock valued at $14,125,000 after buying an additional 21,471 shares in the last quarter. Finally, Sollinda Capital Management LLC purchased a new position in Johnson & Johnson in the 3rd quarter valued at about $211,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.2 %

Shares of NYSE JNJ opened at $160.13 on Monday. The firm has a market cap of $385.53 billion, a price-to-earnings ratio of 23.17, a PEG ratio of 2.84 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The business’s 50 day moving average is $163.31 and its two-hundred day moving average is $155.59.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.66 earnings per share. Research analysts predict that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Analyst Ratings Changes

A number of research analysts have weighed in on JNJ shares. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. The Goldman Sachs Group decreased their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Sanford C. Bernstein raised their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $175.93.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.